Skip to main content
main-content

Sodium-glucose cotransporter 2 (SGLT2) inhibitors

medwireNews top story

Cardioprotective benefits of dapagliflozin extend beyond people with diabetes

Heart failure

Treatment with dapagliflozin is associated with a significant reduction in the risk for heart failure worsening or cardiovascular death in people with heart failure and reduced ejection fraction regardless of whether or not they have diabetes, shows an exploratory analysis of DAPA-HF trial data.

medwireNews top story

Lower gout risk with SGLT2 inhibitors vs GLP-1 receptor agonists

Gout

People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.

medwireNews top story

CVD-REAL 3: Renal benefits of SGLT2 inhibitors confirmed in real-world study

Kidneys

Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.

Expert opinion editorial

Cardiorenal syndromes and SGLT2 inhibitor usage

Cardiorenal syndromes and SGLT2 inhibitor usage

Sanjay Kalra explores the intrinsic link between the cardiovascular and renal systems, focusing on whether the SGLT2 inhibitor class has a role to play in diabetic patients with cardiorenal comorbidity [read more].

Get more on: SGLT2 inhibitors | Nephropathy | Cardiovascular disease 

medwireNews top story

Real-world data reassure on severe UTI risk with SGLT2 inhibition

Urine test strip

The risk for severe urinary tract infections among people with type 2 diabetes in the real-world setting may be no greater with use of sodium-glucose cotransporter 2 inhibitors than with other modern antidiabetes medications, research suggests.

medwireNews feature

Fournier gangrene: A challenge for risk–benefit communication

Doctor patient consultation

The recent postmarketing data on Fournier gangrene in people taking sodium-glucose cotransporter 2 inhibitors has increased concerns about this very rare but potentially fatal side effect. medwireNews talks to primary care diabetes specialist Kevin Fernando about how the findings affect risk–benefit considerations.

medwireNews top story

Dapagliflozin renoprotective in diabetes patients with preserved kidney function

Kidneys

Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.

ADA 2019

The PIONEER trials

diabetes_pills_syringe
medwireNews top story

Postmarketing data support Fournier gangrene link with SGLT2 inhibitors

Critical care

Fournier gangrene remains very rare, but is more common in people using SGLT2 inhibitors compared with other diabetes medications and has severe consequences, shows research.

medwireNews top story

Canagliflozin may offer renal protection in people with type 2 diabetes and CKD

Pills in hand

Findings from the CREDENCE trial indicate that the SGLT2 inhibitor canagliflozin reduces the risk for renal failure and cardiovascular disease among individuals with type 2 diabetes and albuminuric chronic kidney disease.

medwireNews

05-25-2020 | Heart failure | News

Patients stand to gain years from comprehensive HFrEF therapy

Comprehensive therapy with medications including a SGLT2 inhibitor should provide several additional years of event-free and overall survival for people who have heart failure with reduced ejection fraction, shows an analysis in The Lancet.

05-07-2020 | Dapagliflozin | News

FDA okays dapagliflozin for heart failure with reduced ejection fraction

Click through to read more on this approval

04-29-2020 | Nephropathy | News

Real-world data back renal benefits with SGLT2 inhibition

Use of sodium-glucose cotransporter 2 inhibitors is associated with a reduced risk for renal events in people with type 2 diabetes in clinical practice, say researchers.

At a glance

07-03-2019 | Semaglutide | At a glance | Article

A quick guide to the PIONEER trials

medwireNews rounds up the ongoing, reported, and published trials from the PIONEER oral semaglutide program.

11-28-2018 | SGLT2 inhibitors | At a glance | Article

Real-world studies of SGLT2 inhibition and amputation risk

How many real-world studies have looked at amputation risk in users of SGLT2 inhibitors, and do the findings support or refute the effect found in CANVAS? medwireNews rounds up the research so far.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

09-12-2018 | SGLT2 inhibitors | Article

Comparative risk of genital infections associated with SGLT2 inhibitors: A real‐world retrospective cohort study

Dave CV et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13531

09-05-2018 | Older adults | Review | Article

Diabetes treatment in the elderly: Incorporating geriatrics, technology, and functional medicine

Valencia WM et al. Curr Diab Rep 2018; 18: 95. doi: 10.1007/s11892-018-1052-y

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

Image Credits